	SCHEDULE 2 - Luxembourg													
	Date of publication: 28-June-2023													
	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL		Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)				
	(Art. 1.01)	(Art. 3)	(Schedule 1)	(Art. 3)	(Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		TOTAL OPTION AL	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
HCPs													0	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02					N/A	N/A	0		0	0		0	
	Number of Recipients in aggregate disclosure - Art. 3.02 % of the number of Recipients included in the aggregate disclosure in the total number of Recipients					N/A	N/A	0		0	0		0	
					<u> </u>	N/A	N/A	0%		0%	0%		N/A	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
HCOs													0	
		OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						0			0			0	
	Number of Recipients in aggregate disclosure - Art. 3.02					0			0			0		
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients						0%			0%			N/A	
R & D		AGGREGATE DISCLOSURE												
		Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1 0												